Phathom Pharmaceuticals Inc
$ 8.75
-3.10%
31 Jul - close price
- Market Cap 707,883,000 USD
- Current Price $ 8.75
- High / Low $ 9.49 / 8.66
- Stock P/E N/A
- Book Value -4.30
- EPS -1.25
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -34.89 %
- 52 Week High 18.31
- 52 Week Low 8.03
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Analyst Target Price
$21.90
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-02-26 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 |
| Reported EPS | -0.08 | -0.18 | -0.16 | -0.15 | -0.9 | -1.07 | -1.05 | -1.05 | -1.25 | -1.11 | -1.39 | -0.76 |
| Estimated EPS | -0.15 | -0.3897 | -0.2 | -0.41 | -0.86 | -1.066 | -1.08 | -1.46 | -1.24 | -1.22 | -1.08 | -0.96 |
| Surprise | 0.07 | 0.2097 | 0.04 | 0.26 | -0.04 | -0.004 | 0.03 | 0.41 | -0.01 | 0.11 | -0.31 | 0.2 |
| Surprise Percentage | 46.6667% | 53.8106% | 20% | 63.4146% | -4.6512% | -0.3752% | 2.7778% | 28.0822% | -0.8065% | 9.0164% | -28.7037% | 20.8333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAT
2026-08-01 03:10:43
Phathom Pharmaceuticals (PHAT) stock slid 3.1% to US$8.75 despite reporting its first quarter of operating profit on a cash basis, excluding stock-based compensation, with revenue of US$74.3m. This breakthrough included US$1.6m of positive operating cash flow, narrowing its GAAP net loss to US$17.6m. While bulls highlight growing VOQUEZNA sales and disciplined spending, bears are concerned about concentration risk, pricing pressures, and the stock's 27% decline over 90 days.
2026-07-31 19:07:00
SueWallSt, powered by Levi & Korsinsky LLP, has launched an investigation into Phathom Pharmaceuticals (NASDAQ: PHAT) regarding potential securities law violations. The investigation focuses on Phathom's FY 2026 revenue guidance, which was initially maintained at $320 million to $345 million but later cut to $310 million to $325 million, causing a decline in PHAT shares. Investors who suffered losses after purchasing PHAT stock are encouraged to contact SueWallSt for a free case evaluation.
2026-07-31 15:40:58
Phathom Pharmaceuticals (NASDAQ: PHAT) had approximately 380 employees worldwide as of March 2026, marking a 205.2% growth since 2023 but a 5.4% year-over-year decrease. The company is actively hiring, with 49 job postings in 2026 and an accelerating hiring velocity of 111 new roles per month. The workforce is primarily in the United States, with an average salary of $145,410 and a median employee tenure of 1.9 years.
2026-07-31 14:09:27
SueWallSt.com has announced an investigation into potential securities law violations involving Phathom Pharmaceuticals (NASDAQ: PHAT). The investigation stems from the company's decision to trim its full-year 2026 revenue guidance to $310 million to $325 million, weeks after affirming a higher outlook of $320 million to $345 million. Investors who suffered losses after the share price declined are encouraged to contact SueWallSt for a free case evaluation.
2026-07-31 09:10:43
Phathom Pharmaceuticals (PHAT) achieved its first-ever positive operating profit and cash from operations in Q2 2026, with revenue growing 88% year-over-year to $74.3 million. Despite this, full-year revenue guidance was slightly lowered due to prior authorization friction for Voquezna, and the company anticipates using cash for the remainder of the year. Strategic investments, including a Phase 3 GERD trial, are expected to increase operating expenses in the second half of 2026, while competitive pressure from a new PCAB could impact gross-to-net discounts.
2026-07-31 03:10:43
Phathom Pharmaceuticals experienced a significant drop of over 19% in early trading, marking its largest percentage decrease since May 2025. The stock is currently trading at $10.15, down $2.43 from its previous close, with trading volume significantly higher than its 50-day average. This decline also affects its year-to-date performance, which is now down 16.29%.
